2483-48-9

Basic information

• Product Name: (+)-(S)-N₂,N₆-bis[(1,1-dimethylethoxy)carbonyl]-lysine methyl ester
• Synonyms: (+)-(S)-N₂,N₆-bis[(1,1-dimethylethoxy)carbonyl]-lysine methyl ester
• CAS NO: 2483-48-9
• Molecular Weight: 360.451
• Mol File: 2483-48-9.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: (+)-(S)-N₂,N₆-bis[(1,1-dimethylethoxy)carbonyl]-lysine methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-(S)-N₂,N₆-bis[(1,1-dimethylethoxy)carbonyl]-lysine methyl ester(2483-48-9)
• EPA Substance Registry System: (+)-(S)-N₂,N₆-bis[(1,1-dimethylethoxy)carbonyl]-lysine methyl ester(2483-48-9)

Safety Data

• Hazardous Substances Data: 2483-48-9(Hazardous Substances Data)

Usage

General Description

(+)-(S)-N2,N6-bis[(1,1-dimethylethoxy)carbonyl]-lysine methyl ester is a chemical compound that is commonly used in solid-phase peptide synthesis and as a building block in the production of polypeptides. It is a derivative of lysine, an essential amino acid, and has two protected carboxyl groups, making it a useful intermediate in peptide synthesis. The methyl ester group on the lysine side chain also provides protection for the amino group, allowing for selective deprotection and further modification of the peptide. (+)-(S)-N₂,N₆-bis[(1,1-dimethylethoxy)carbonyl]-lysine methyl ester is important in the field of biochemistry and pharmaceutical research due to its role in the development and synthesis of various peptides for therapeutic and research purposes.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 2389-48-2 N-ε-tert-butoxycarbonyl-L-lysine methyl ester hydrochloride 
• 3017-32-1 (S)-methyl 2-amino-6-(tert-butoxycarbonylamino)hexanoate 
• 657-27-2 L-Lysine hydrochloride 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 588719-10-2 N-benzyloxycarbonyl-ω-{3-[(N,N-dimethylaminophenyl)-4'-diazenyl]benzoyl}lysine methyl ester 
• 26348-68-5 N-(benzyloxycarbonyl)lysine methyl ester hydrochloride 
• 2483-46-7 Boc-Lys(Boc)-OH 
• 74-88-4 methyl iodide 
• 100-36-7 N,N-diethylethylenediamine 
• 588719-15-7 N-benzyloxycarbonyl-N-tert-butyloxycarbonyl-ω-{3-[(N,N-dimethylaminophenyl)-4'-diazenyl]benzoyl}lysine methyl ester 
• 67-56-1 methanol 
• 56-87-1 L-lysine 
• 13515-95-2 lysine methyl ester dihydrochloride 

Downstream Products

• 819871-13-1 [5-tert-butoxycarbonylamino-5-(1-methyl-2-phenylethylcarbamoyl)pentyl]carbamic acid tert-butyl ester 
• 687-64-9 L-lysine methyl ester 
• 1374137-98-0 tert-butyl [(5S)-5-[(tert-butoxycarbonyl)amino]-6-{[tert-butyl(diphenyl)silyl]oxy}hexyl]carbamate 
• 1374138-11-0 N-[(2R,5S)-5-{[(4-aminophenyl)sulfonyl](3-methylbutyl)amino}-2-fluoro-6-hydroxy-hexyl]-Nα-(methoxycarbonyl)-β-phenyl-L-phenylalaninamide 
• 1374138-12-1 N-[(2S,5S)-5-{[(4-aminophenyl)sulfonyl](3-methylbutyl)amino}-2-fluoro-6-hydroxy-hexyl]-Nα-(methoxycarbonyl)-β-phenyl-L-phenylalaninamide 
• 1374137-87-7 N-[(5S)-5-{[(4-aminophenyl)sulfonyl](3-methylbutyl)amino}-2-fluoro-6-hydroxy-hexyl]-Nα-(methoxycarbonyl)-β-phenyl-L-phenylalaninamide 
• 1374138-10-9 N-[(5S)-2-fluoro-6-hydroxy-5-{(3-methylbutyl)[(4-nitrophenyl)sulfonyl]amino}hexyl]-Nα-(methoxycarbonyl)-β-phenyl-L-phenylalaninamide 
• 1374138-09-6 N-[(5S)-6-{[tert-butyl(diphenyl)silyl]oxy}-2-fluoro-5-{(3-methylbutyl)[(4-nitrophenyl)sulfonyl]amino}hexyl]-Nα-(methoxycarbonyl)-β-phenyl-L-phenylalaninamide 
• 1374138-08-5 N-{(5S)-6-{[tert-butyl(diphenyl)silyl]oxy}-2-fluoro-5-[(3-methylbutyl)amino]hexyl}-Nα-(methoxycarbonyl)-β-phenyl-L-phenylalaninamide 
• 1374138-07-4 benzyl [(2S)-1-{[tert-butyl(diphenyl)silyl]oxy}-5-fluoro-6-{[N-(methoxycarbonyl)-β-phenyl-L-phenylalanyl]amino}hexan-2-yl](3-methylbutyl)carbamate 
• 1374138-06-3 benzyl [(2S)-6-amino-1-{[tert-butyl(diphenyl)silyl]oxy}-5-fluorohexan-2-yl](3-methylbutyl)carbamate 
• 1374138-05-2 benzyl [(2S)-1-{[tert-butyl(diphenyl)silyl]oxy}-5-fluoro-6-(tritylamino)hexan-2-yl](3-methylbutyl)carbamate 
• 1374138-04-1 benzyl [(2S)-1-{[tert-butyl(diphenyl)silyl]oxy}-5-fluoro-6-oxohexan-2-yl](3-methylbutyl)carbamate 
• 1374138-03-0 benzyl [(2S)-1-{[tert-butyl(diphenyl)silyl]oxy}-6-oxohexan-2-yl](3-methylbutyl)carbamate 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES

The present invention is directed to processes for the preparation of lisdexamfetamine and related derivatives, wherein the processes comprise coupling to racemic or enantiomerically enriched amphetamine and wherein the resulting product is advantageously enantiomerically or diastereomerically enriched in the desired stereoisomer.

HIV PROTEASE INHIBITORS

Compounds of Formula I are disclosed wherein R1, R2, R3A, R3B, R4A, R4B, R5A, R5B, R6A, R6B, R7, R8 and R9 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

HIV PROTEASE INHIBITORS

Compounds of Formula I are disclosed: (I), wherein XA, k, R1, R2, R3, R4, R5, R5A, R6, R6A, R7 and R8 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.